Melanoma patients in the European Union now have access to a treatment built from two antibodies fused into one infusion. The European approval came in September 2022, six months after the United States cleared the same drug. The medication is nivolumab/relatlimab, sold as Opdualag. It is a fixed-dose combination, given intravenously.
The U.S. Food and Drug Administration designated it a first-in-class medication. That label is not handed out lightly. It signals a genuinely new approach, not just another variation on an existing theme. For melanoma, a skin cancer that kills thousands each year, new options arrive slowly. This one arrived in March 2022 on the American side of the Atlantic, then crossed over in September.
Two distinct antibodies make up the drug. Nivolumab blocks PD-1, a receptor that cancer cells use to switch off immune attacks. Block PD-1, and the immune system stays switched on. That part is not new — nivolumab has been used alone for years. The novelty is relatlimab. It blocks LAG-3, another receptor that reins in immune responses. Cancer cells often exploit LAG-3 as a second brake. By blocking both PD-1 and LAG-3 at once, the combination attacks melanoma from two angles.
Think of it as releasing two parking brakes instead of one. The immune system gets a double signal to move forward and attack tumor cells. Early data from clinical trials suggested this dual blockade could improve outcomes over PD-1 blockade alone. The FDA agreed. So did the European Medicines Agency.
The approval in Europe extends access to a large patient population. Melanoma incidence has risen steadily in many European countries. Sun exposure, aging populations, and better detection all play a role. For patients whose disease has spread or cannot be surgically removed, systemic therapy is the main option. Before immune checkpoint inhibitors, that meant chemotherapy with modest results. The arrival of PD-1 inhibitors changed the landscape. Now LAG-3 blockade adds another tool.
Opdualag is a fixed-dose combination. That means patients receive both antibodies in a single infusion, at a set ratio. No separate vials, no complex dosing schedules. For clinics and patients alike, that simplicity matters. Cancer treatment is already complicated enough.
The drug’s path to approval was not a straight line. Nivolumab was already well understood. Relatlimab was the unknown variable. Early research into LAG-3 as a target stretched back more than a decade. Many drug developers tried and failed to turn that biology into a working therapy. Bristol Myers Squibb, the company behind Opdualag, succeeded where others fell short. The result is a first-in-class drug that validates LAG-3 as a viable target.
That matters beyond melanoma. If LAG-3 blockade works in skin cancer, researchers will test it in other tumors. Lung cancer, kidney cancer, and lymphoma are all candidates. The melanoma approval opens the door.
For now, the focus stays on skin cancer. Melanoma is the deadliest form of skin cancer, though not the most common. It accounts for the vast majority of skin cancer deaths. Late-stage melanoma is notoriously aggressive. Patients diagnosed with metastatic disease face a grim prognosis without effective treatment. Opdualag offers a new line of defense.
The European approval arrived in September 2022. The U.S. approval came in March 2022. Between those two dates, clinics on both continents began integrating the drug into treatment protocols. Insurance coverage, reimbursement, and physician education all take time. But the regulatory green light is the essential first step.
Two antibodies, one infusion, a new mechanism. That is the story of nivolumab/relatlimab. It is not a cure. No single drug is. But it is a meaningful advance in a field that needs every weapon it can get.
